Published in Gene Therapy Weekly, January 20th, 2005
The conclusion of the phase I clinical trial of LACTIN-V for recurrent bacterial vaginosis (RBV) represents a significant milestone for Osel. The product is also midway through a second phase I trial for recurrent urinary tract infection (RUTI) under the direction of Dr. Walter Stamm, MD, professor, medicine/infectious diseases, at the University of Washington, Seattle, Washington. Osel plans to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.